Product Description
Mechanisms of Action: SARM Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Breast Cancer|Oncology Solid Tumor Unspecified *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Oncternal Therapeutics
Company Location: SAN DIEGO CA 92130
Company CEO: James B. Breitmeyer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-002176-39 | P3 |
Active, not recruiting |
Breast Cancer |
2024-12-22 |
|
| QUALITY | P2 |
Active, not recruiting |
Obesity |
2024-12-20 |